MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$9,549K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales of marketable securities
Proceeds from debt issuance
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Payments of long-term debt
Sales and marketing
General and administrative
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Gross profit
13,441
12,986
11,057
8,961
General and administrative
8,936
8,625
7,498
7,703
Sales and marketing
9,347
8,276
7,115
6,248
Medical education
1,803
1,307
1,727
1,126
Research and development
3,391
3,754
3,217
1,525
Total other (income) expense
-117
597
728
-1,088
Net loss
-10,153
-8,379
-7,772
-8,729
Depreciation and amortization
1,133
1,132
980
843
Amortization of debt discounts
50
50
63
64
Credit losses, net of recoveries
-
-
153
-
Loss on disposal of long-lived assets
-
-
-100
-
Stock-based compensation expense
1,081
726
381
298
Realized (gain) loss on marketable securities
-201
161
2
195
Change in fair value of warrant liabilities and series e purchase option
0
-
0
-1,159
Change in fair value of convertible notes, net
-
-
1
2,216
Loss on extinguishment of debt
-589
-
-
-
Other
-172
-120
166
-67
Trade accounts receivable
468
2,389
1,239
240
Inventory
1,091
238
2,233
2,277
Prepaid expenses
624
187
-192
1,019
Accounts payable
997
-3,219
1,580
807
Other current assets and liabilities
-721
-187
821
-769
Net cash used in operating activities
-7,392
-12,358
-8,783
-8,555
Fixed asset purchases
2,157
2,735
2,282
2,815
Purchases of marketable securities
0
18,170
23,909
75,105
Sales of marketable securities
22,601
17,783
8,909
5,484
Net cash provided by (used in) investing activities
20,444
-3,122
-17,282
-72,436
Proceeds from exercise of common stock options
423
101
231
537
Proceeds from exercise of preferred stock warrants
0
0
0
93
Proceeds from series e convertible preferred stock, net of issuance cost
0
0
0
-45
Payments of long-term debt
15,000
-
-
-
Proceeds from debt issuance
15,000
-
-
-
Proceeds from the issuance of convertible notes, net of issuance costs
-
-
0
39,863
Payments of debt issuance and extinguishment costs
507
-
-
-
Proceeds from ipo, net of commissions and issuance costs
-
-
-2,229
66,441
Payment of deferred ipo offering costs
0
-
-
-
Net cash provided by financing activities
-84
101
-1,998
108,871
Net change in cash for period
12,968
-15,379
-28,063
27,880
Cash and cash equivalents, beginning of period
11,492
26,871
54,934
6,123
Cash and cash equivalents, end of period
24,460
11,492
26,871
54,934
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales of marketable
securities
$22,601K
(33.66%↑ Y/Y)
Net cash provided by
(used in) investing...
$20,444K
(447.75%↑ Y/Y)
Canceled cashflow
$2,157K
Net change in cash
for period
$12,968K
(-38.04%↓ Y/Y)
Canceled cashflow
$7,476K
Fixed asset purchases
$2,157K
(-6.66%↓ Y/Y)
Depreciation and
amortization
$1,133K
(-18.19%↓ Y/Y)
Stock-based compensation
expense
$1,081K
(241.01%↑ Y/Y)
Accounts payable
$997K
(1.53%↑ Y/Y)
Other current assets
and liabilities
-$721K
(63.10%↑ Y/Y)
Loss on
extinguishment of debt
-$589K
Realized (gain) loss on
marketable securities
-$201K
(-197.10%↓ Y/Y)
Other
-$172K
(-73.74%↓ Y/Y)
Amortization of debt
discounts
$50K
(-60.32%↓ Y/Y)
Proceeds from debt
issuance
$15,000K
Proceeds from exercise of
common stock options
$423K
(180.13%↑ Y/Y)
Net cash used in
operating activities
-$7,392K
(34.43%↑ Y/Y)
Net cash provided by
financing activities
-$84K
(-100.22%↓ Y/Y)
Canceled cashflow
$4,944K
Canceled cashflow
$15,423K
Gross profit
$13,441K
(-16.95%↓ Y/Y)
Net loss
-$10,153K
(57.44%↑ Y/Y)
Payments of long-term
debt
$15,000K
Canceled cashflow
$13,441K
Inventory
$1,091K
(-65.10%↓ Y/Y)
Prepaid expenses
$624K
(140.00%↑ Y/Y)
Trade accounts
receivable
$468K
(-74.29%↓ Y/Y)
Payments of debt issuance
and extinguishment...
$507K
Sales and marketing
$9,347K
(-8.20%↓ Y/Y)
General and
administrative
$8,936K
(-19.01%↓ Y/Y)
Research and development
$3,391K
(13.45%↑ Y/Y)
Medical education
$1,803K
(-15.59%↓ Y/Y)
Total other (income)
expense
-$117K
(99.15%↑ Y/Y)
Buy us a coffee
SHOULDER INNOVATIONS, INC. (SI)
SHOULDER INNOVATIONS, INC. (SI)